IBDEI0GY ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8232,0)
 ;;=362.29^^58^607^63
 ;;^UTILITY(U,$J,358.3,8232,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8232,1,3,0)
 ;;=3^Nondiabetic PR
 ;;^UTILITY(U,$J,358.3,8232,1,4,0)
 ;;=4^362.29
 ;;^UTILITY(U,$J,358.3,8232,2)
 ;;=^268619
 ;;^UTILITY(U,$J,358.3,8233,0)
 ;;=362.30^^58^607^40
 ;;^UTILITY(U,$J,358.3,8233,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8233,1,3,0)
 ;;=3^Hemiretinal Vein Occlusion
 ;;^UTILITY(U,$J,358.3,8233,1,4,0)
 ;;=4^362.30
 ;;^UTILITY(U,$J,358.3,8233,2)
 ;;=^105640
 ;;^UTILITY(U,$J,358.3,8234,0)
 ;;=362.37^^58^607^9
 ;;^UTILITY(U,$J,358.3,8234,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8234,1,3,0)
 ;;=3^CRVO-Partial
 ;;^UTILITY(U,$J,358.3,8234,1,4,0)
 ;;=4^362.37
 ;;^UTILITY(U,$J,358.3,8234,2)
 ;;=^268627
 ;;^UTILITY(U,$J,358.3,8235,0)
 ;;=362.50^^58^607^51
 ;;^UTILITY(U,$J,358.3,8235,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8235,1,3,0)
 ;;=3^Mac Degen,Senile/Atrophy
 ;;^UTILITY(U,$J,358.3,8235,1,4,0)
 ;;=4^362.50
 ;;^UTILITY(U,$J,358.3,8235,2)
 ;;=^73072
 ;;^UTILITY(U,$J,358.3,8236,0)
 ;;=362.70^^58^607^28
 ;;^UTILITY(U,$J,358.3,8236,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8236,1,3,0)
 ;;=3^Degen/Hered Disorder
 ;;^UTILITY(U,$J,358.3,8236,1,4,0)
 ;;=4^362.70
 ;;^UTILITY(U,$J,358.3,8236,2)
 ;;=^268650
 ;;^UTILITY(U,$J,358.3,8237,0)
 ;;=362.74^^58^607^91
 ;;^UTILITY(U,$J,358.3,8237,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8237,1,3,0)
 ;;=3^Retinitis Pigmentosa
 ;;^UTILITY(U,$J,358.3,8237,1,4,0)
 ;;=4^362.74
 ;;^UTILITY(U,$J,358.3,8237,2)
 ;;=^105693
 ;;^UTILITY(U,$J,358.3,8238,0)
 ;;=362.75^^58^607^50
 ;;^UTILITY(U,$J,358.3,8238,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8238,1,3,0)
 ;;=3^Mac Degen,Juvenile
 ;;^UTILITY(U,$J,358.3,8238,1,4,0)
 ;;=4^362.75
 ;;^UTILITY(U,$J,358.3,8238,2)
 ;;=^268656
 ;;^UTILITY(U,$J,358.3,8239,0)
 ;;=362.76^^58^607^74
 ;;^UTILITY(U,$J,358.3,8239,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8239,1,3,0)
 ;;=3^RPE Hypertrophy
 ;;^UTILITY(U,$J,358.3,8239,1,4,0)
 ;;=4^362.76
 ;;^UTILITY(U,$J,358.3,8239,2)
 ;;=^268657
 ;;^UTILITY(U,$J,358.3,8240,0)
 ;;=362.82^^58^607^85
 ;;^UTILITY(U,$J,358.3,8240,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8240,1,3,0)
 ;;=3^Retinal Exudates
 ;;^UTILITY(U,$J,358.3,8240,1,4,0)
 ;;=4^362.82
 ;;^UTILITY(U,$J,358.3,8240,2)
 ;;=^268659
 ;;^UTILITY(U,$J,358.3,8241,0)
 ;;=363.12^^58^607^68
 ;;^UTILITY(U,$J,358.3,8241,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8241,1,3,0)
 ;;=3^Periph Disem Choroiditis
 ;;^UTILITY(U,$J,358.3,8241,1,4,0)
 ;;=4^363.12
 ;;^UTILITY(U,$J,358.3,8241,2)
 ;;=^268675
 ;;^UTILITY(U,$J,358.3,8242,0)
 ;;=363.15^^58^607^1
 ;;^UTILITY(U,$J,358.3,8242,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8242,1,3,0)
 ;;=3^AMPPE
 ;;^UTILITY(U,$J,358.3,8242,1,4,0)
 ;;=4^363.15
 ;;^UTILITY(U,$J,358.3,8242,2)
 ;;=^268678
 ;;^UTILITY(U,$J,358.3,8243,0)
 ;;=363.33^^58^607^96
 ;;^UTILITY(U,$J,358.3,8243,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8243,1,3,0)
 ;;=3^Scars of Post Pole of Chorioret
 ;;^UTILITY(U,$J,358.3,8243,1,4,0)
 ;;=4^363.33
 ;;^UTILITY(U,$J,358.3,8243,2)
 ;;=^268681
 ;;^UTILITY(U,$J,358.3,8244,0)
 ;;=363.41^^58^607^97
 ;;^UTILITY(U,$J,358.3,8244,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8244,1,3,0)
 ;;=3^Senile Atrophy of Choroid
 ;;^UTILITY(U,$J,358.3,8244,1,4,0)
 ;;=4^363.41
 ;;^UTILITY(U,$J,358.3,8244,2)
 ;;=^268686
 ;;^UTILITY(U,$J,358.3,8245,0)
 ;;=363.43^^58^607^4
 ;;^UTILITY(U,$J,358.3,8245,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8245,1,3,0)
 ;;=3^Angioid Streaks
 ;;^UTILITY(U,$J,358.3,8245,1,4,0)
 ;;=4^363.43
 ;;^UTILITY(U,$J,358.3,8245,2)
 ;;=^7492
